Avdoralimab

DB16392InvestigationalProtein Based Therapies

Avdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).

Mechanism: Avdoralimab binds and inhibits C5a receptors (C5aR) expressed on myeloid-derived suppressor cells and neutrophils. C5a is often associated with tumors; by blocking the binding of C5a to C5aR, Advoralimab reduces the activation of MDSC and neutrophils in tumor microenvironments, thus exhibiting anti-tumor activity.
Curator reviewed
Code names: ANTI-C5AR-215 · IPH-5401 · NN-8210 · NNC-0215-0384

Resolves to

Compound

UNIIDW4CE8MKS9CAS2226393-85-5

Targets

P21730C5AR1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Avdoralimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account